Compare Tango Therapeutics Inc. (TNGX) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs UnitedHealth Group Inc — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while UnitedHealth Group Inc trades at $397.51 (market cap $355.11B). The key difference: UnitedHealth Group Inc is far larger — about 94.9× Tango Therapeutics Inc.'s market cap, and UnitedHealth Group Inc pays a 2.35% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| TNGX | UNH | |
|---|---|---|
Market Cap | $3.74B | $355.11B |
Volume | 3,438,781 | 7,759,080 |
Sector | Health | Health |
52-Week High | $32.90 | $436.35 |
52-Week Low | $7.50 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $2.76B | $396.97B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
UnitedHealth Group (UNH) trades at $377.76, down 0.2% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.38 surpassing the $4.91 expectation. Revenue reached $447.57 billion in 2025, though net income margin declined to 2.69%. Recent news highlights dividend payments and strategic moves like the TPG deal for WellMed clinics.
UNH presents a favorable outlook with a consensus price target of $470.11, implying significant upside. Strengths include robust cash flow, a dominant market position, and AI investments in Optum. Risks involve regulatory pressures, rising medical costs, and debt levels. The stock remains a core holding for growth-oriented investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
